product
  • company
  • recruit
SNS 공유하기
페이스북 공유하기 트위터 공유하기

Pharmaceuticals

We have secured competitive edge in the Red Bio market,
based on our superior technologies and R&D capabilities.
Based on our superior biotechnology and R&D capabilities accumulated since 1980s,
we have been successful in developing a variety of original products including Korea's
first growth hormone for children, new drugs for diabetes, etc. At the same time,
we have continuously expanded our competitive edge through cooperation with global
pharmaceutical companies.

Product info

Main Businesses

Bio pharmaceuticals
Growth Stimulation, Infertility Treatment,
Renal Diseases, Biosimilar, etc.
HA products
Musculoskeletal Diseases,
Cosmetic Surgery
Synthetic drugs
Diabetes,
Cardiovascular Drugs
Diagnostic kits
Immunodiagnosis,
Molecular Diagnosis

Core Products

  • EutropinGrowth hormone deficiency
  • Hyruan OneOsteoarthritis
  • Zemiglo / Zemimet SR Tab.Non-insulin dependent diabetes mellitus
  • FollitropeInduction of ovulation
  • Hyruan PlusOsteoarthritis
  • LevacalmHypertension
  • EspogenAnemia in patients with chronic renal failure

Key Pipelines

Class Product Indication DS PC Clinical Trial NDA
P I P II P III
Bio LBEC0101 Enbrel biosimilar
LBAL Humira biosimilar
NCE
(New Chemical Entity)
Zemiglo Indication expansion for insulin combined therapy
LC280126 Myocardial infarction
Anti-cancer supportive drugs
LC510255 Inflammatory diseases
LC541239 Type 2 diabetes
LC65AOD3 Type 2 diabetes
Combination drug ZemiMet SR Combination drugs for diabetes
ZemiStatin Diabetes/Dyslipidemia
HA filler Highly cohesive Yvoire filler Fillers for cosmetic surgery
Fillers containing new substances Fillers for cosmetic surgery
전체메뉴 닫기
company product Download Product Info.
Basic Materials & Chemicals
NCC
ABS
Acrylates/SAP
Rubbers/
Specialty
Polymers
Energy Solutions
IT&E. Materials
Optical Materials
Advanced Materials
Life Sciences
recruit
Ideal Employee
Ideal Employee
Personnel Management System
Personnel Management Principles
Talent Development
etc.